Navigation Links
Diabetes drug linked to increased risk of heart failure
Date:8/20/2009

Rosiglitazone, a drug used to treat type 2 diabetes, is associated with an increased risk of heart failure and death among older patients compared to a similar drug (pioglitazone), concludes a study published on bmj.com today.

As such, the researchers say it is difficult to advocate continued use of rosiglitazone for most patients.

Rosiglitazone and pioglitazone belong to a class of drugs called thiazolidinediones and are widely used for the treatment of type 2 diabetes. They help to control blood sugar levels, but both drugs can also cause side effects including weight gain, fluid retention and heart failure.

It is unclear whether there are clinically important differences in the cardiac safety of these two drugs, so researchers in Canada compared the risk of heart attack, heart failure and death in patients treated with rosiglitazone and pioglitazone.

Using prescription records, they identified nearly 40,000 patients aged 66 years and older who started treatment with either rosiglitazone or pioglitazone between April 2002 and March 2008.

Data on hospital admission for either a heart attack or heart failure during the six-year study period were recorded and deaths were identified from a national database.

Detailed analysis showed that patients treated with pioglitazone had a significantly lower risk of heart failure and death compared to patients treated with rosiglitazone, but there was no significant difference in the risk of heart attack.

The researchers estimate that, for every 93 patients treated with rosiglitazone rather than pioglitazone, one additional cardiovascular event or death would be predicted to occur annually.

"Our findings suggest clinically important differences in the cardiovascular safety profiles of rosiglitazone and pioglitazone in clinical practice," say the authors. "Given the accumulating evidence of harm with rosiglitazone treatment and the lack of a distinct clinical advantage for the drug over pioglitazone, it is reasonable to question whether ongoing use of rosiglitazone is justified," they conclude.

This study reinforces the message that thiazolidinediones should be avoided in heart failure patients, but the claim that pioglitazone is safer than rosiglitazone is not fully supported by the data, say two experts from the Universities of Bath and Surrey in an accompanying editorial.

Although it may be tempting to move away from prescribing thiazolidinedione altogether, they write, long term follow-up data for newer products are not yet available.

Given that randomised trials are unlikely ever to provide the full picture, they suggest that enhancements to healthcare databases coupled with well designed studies like this one are essential for determining the full risk-benefit profile of medicines. People who have concerns regarding their diabetes treatment are urged to consult their GP and not to discontinue taking their medication.


'/>"/>

Contact: Emma Dickinson
edickinson@bmj.com
44-207-383-6529
BMJ-British Medical Journal
Source:Eurekalert

Related medicine news :

1. Type 1 diabetes linked to immune response to wheat
2. Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 & Type 2 Diabetes
3. Scarring key to link between obesity and diabetes
4. Dwayne Johnson, Novo Nordisk and the Entertainment Industry Foundation Educate Families about Healthy Living and Diabetes
5. The Jones Center for Diabetes & Endocrine Wellness Selects Retasure to Enhance Diabetes Care
6. Found: A gene that may play a role in type 1 diabetes
7. Taking the needles sting out of diabetes
8. Cell Conversion Shows Promise for Diabetes Treatment
9. AADE, Emory University and Johnson & Johnson Diabetes Institute Partner to Educate and Improve Access to Care for Atlanta-area Minorities with Diabetes
10. Sex Hormone Protein May Predict Type 2 Diabetes
11. BD and Direct Relief International Team Up to Provide Free Diabetes Insulin Injection Products to Americans Impacted by the Economic Downturn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... ... Periodontist Dr. Dan Holtzclaw in media for its creos™ line of bone regenerative ... by Dr. Holtzclaw in which he utilizes creos™ allo.gain™ bone graft for a ...
(Date:1/20/2017)... ... ... Source Vitál Apothecary, a skin and body care company dedicated to creating ... a successful visit to the 2017 ECRM Diet, Vitamin & Sports Nutrition Conference in ... nutritional, sports and health industries a chance to meet in private sessions with some ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... ... wellness products to enhance people’s everyday lives, recently attended the January ECRM Trade ... , ATP Science is known for its large range of supplements that keep ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well has ... 002. The drinks have been produced in collaboration with Zlatan Ibrahimovic and have ... workout. , After a successful launch in Sweden last year, the next generation ...
(Date:1/20/2017)... ... 2017 , ... “I Forgive You”: a fine examination of how God handles sin, including ... of published author, Stephen Miller, who, for over ten long years has been waiting to ... in Trinidad and Tobago, he has been serving the Lord for over twenty years, and ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... YORK , Jan. 19, 2017 ... USD 233.7 billion by 2025, according to a ... market is anticipated to be predominantly driven by ... resulting into the large-scale production of new and ... the influx of drugs at an unprecedented rate ...
(Date:1/19/2017)... 2017 Report Details ... Alzheimer,s Disease Therapeutics ... – our new study reveals trends, R&D progress, and ... affecting the Alzheimer,s disease therapeutics and diagnostics market. Our ... questions: - How is the Alzheimer,s disease therapeutics and ...
(Date:1/19/2017)... 19, 2017 According to a study conducted ... set to witness a CAGR of 6.5% during the forecast period ... will continue to be the leading market for cryotherapy globally during ... ... on ensuring affordable and adequate supply of gas in order to ...
Breaking Medicine Technology: